|Last Price$5.25||Day Change (%)3.35%|
|Open Price$5.10||Day Change ($)0.17|
|Day Range5.08–5.27||52-Week Range2.69–7.67|
As of Wed 11/25/2015 5:00:00 PM | USD
Research and Markets: Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H2 2015
With "massive" student debt loads receding in the rearview mirror, a young professional couple fires up their investment plan.
Berkshire's non-insurance operations continue to be an added source of stability while reinsurance operations continue to struggle.
Wide-moat Berkshire Hathaway saw solid top-line results from each of its main segments, but losses from investments, derivatives, and eliminations sent earnings lower.
Noninsurance operations continue to be a source of stability, while its insurance business overall may see more meager results during the next couple of years.
Just about every segment at Berkshire was dealing with elevated costs during the first quarter.
Morningstar's Gregg Warren says Berkshire's sterling balance sheet, strong business, and unique structure will sustain the firm's competitive standing--even without Buffett.
Alternative methods have some use, but we think discounted cash flow is the most fundamentally sound way to value the conglomerate, as we discuss in the final installment of our 5-part series.